ResMed (RMD) Misses Q2 EPS by 5c
Tweet
Share
E-mail
Get Alerts RMD Hot Sheet
Price: $224.99 -1.5%
EPS Growth %: +5.5%
Financial Fact:
Total other income, net: -1.22M
Today's EPS Names:
VIVO, OCCI, ALZN, More
EPS Growth %: +5.5%
Financial Fact:
Total other income, net: -1.22M
Today's EPS Names:
VIVO, OCCI, ALZN, More
Join SI Premium – FREE
ResMed (NYSE: RMD) reported Q2 EPS of $1.47, $0.05 worse than the analyst estimate of $1.52. Revenue for the quarter came in at $894.9 million versus the consensus estimate of $935.3 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westinghouse said to seek over $50 billion valuation in planned IPO
- Anthropic delays planned IPO from October to November - WSJ
- Barclays says AI trade is maturing, favors greater diversification
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
